<DOC>
	<DOCNO>NCT01392872</DOCNO>
	<brief_summary>Multiple Sclerosis first cause neurological handicap France . The importance cognitive disability , evaluation impact patient ' life comprehend recently . Immunosuppressants represent new treatment Multiple Sclerosis ( MS ) imply lot constraint . This study evaluate impact treatment cognitive disability , tiredness state , emotion quality life general , lengthened period .</brief_summary>
	<brief_title>Cognitive Disability Quality Life Patients Suffering From Multiple Sclerosis Treatment With Immunosuppressant</brief_title>
	<detailed_description>Multiple Sclerosis first cause neurological handicap France . The importance cognitive disability , evaluation impact patient ' life comprehend recently . Immunosuppressants represent new treatment MS imply lot constraint . This study evaluate impact treatment cognitive disability , tiredness state , emotion quality life general , lengthened period .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<criteria>Clinical diagnosis Relapsing MS since least 6 month le 10 year Neurological state stable since least 1 month Moderate Handicap ( EDSS â‰¤ 5,5 ) Secondary Progressive MS Patient attack Patient experience en MS relapse recover systemic corticosteroid previous 1 month Depressive patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Immunosuppressant</keyword>
	<keyword>Quality life</keyword>
	<keyword>Cognitive function</keyword>
	<keyword>Relapsing Multiple Sclerosis</keyword>
</DOC>